New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that ...

GLP-1 drugs like Ozempic and Wegovy can aid weight loss and diabetes, but come with side effects, high costs and unanswered ...

The MarketWatch News Department was not involved in the creation of this content. Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau ...

Karem P. Colindres, D.O. If you’ve heard names like Ozempic®, Wegovy®, or Mounjaro® in the news or on social media, you may be wondering what they are — and why they’re getting so much attention.

In early 2025, around 4.9 million British adults — almost one in ten — are estimated to have recently used, or expressed interest in using, glucagon-like peptide-1 (GLP-1) or dual ...

Drugmakers Novo Nordisk and Eli Lilly and Company have transformed the landscape of chronic weight loss management with the ...

Use of GLP-1s or glucose-dependent insulinotropic polypeptide agonists before upper endoscopy significantly increased the risk for residual gastric volume, according to data published in JAMA Internal ...

Adults with overweight or obesity taking the new generation of weight loss drugs semaglutide and tirzepatide tend to eat ...

Viking Therapeutics Inc. said after-market hours Feb. 11 that it plans to advance its oral dual GLP-1/GIP receptor, VK-2735, into a phase III trial for obesity in the third quarter of 2026. VK-2735 is ...

Tirzepatide vs. semaglutide, which is better? Medical experts agree that tirzepatide has better results, but the right drug for you depends on more.

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a hormone called glucose-dependent insulinotropic polypeptide (GIP) to “help break ...

Two genes involved in gut hormones that influence appetite and digestion may be a factor in how people respond to GLP-1 drugs ...